- Oread Inc has signed a letter of intent to acquire the commercial and clinical manufacturing and pharmaceutical formulation development operations of Roche subsidiary Syntex, based in Palo Alto, California, USA. Syntex will contract with Oread for the development of certain products and their commercial manufacturing. Financial terms were not disclosed, but it is thought that Syntex will become a minority stockholder in the company. The transaction is due to be completed in November this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze